Janux Therapeutics (NASDAQ:JANX) Receives “Outperform” Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a research note released on Friday morning,RTT News reports. The brokerage currently has a $76.00 price objective on the stock, up from their previous price objective of $75.00. JANX has been the topic of a number of other research reports. […]
Wedbush reaffirmed their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a research note released on Friday morning,RTT News reports. The brokerage currently has a $76.00 price objective on the stock, up from their previous price objective of $75.00. JANX has been the topic of a number of other research reports. […]
